Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Aligos Therapeutics, Inc. ALGS

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$-24.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2024 · Revenue 3.6 · Net income -131.2
-50M-100M
201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -2469.0%
-1000%-2000%
201920222025
ROE
FY2023 · ROE -89.5%
-50%
201920222025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -152%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -80.9
-50M-100M
201920222025

Total assetsUSD 88.5M
EquityUSD 53.5M
CashUSD 18.3M
Current ratio3.90×

Equity funds 60% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ALGS, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B◌0.00.00.00.00.0◌
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.1
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.1−0.1
Income tax $B0.00.00.00.00.00.00.0
Net income $B−0.0−0.1−0.1−0.1−0.1−0.1−0.1
Free cash flow $B◌−0.1−0.1−0.1−0.1−0.1−0.0
EPS, diluted $−2.45−20.94−34.20−2.25−3.22−10.87−26.04
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %——−89.5−66.6−63.4——
Shares out B0.010.000.080.040.040.040.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image